OKYO Pharma to Participate in H.C. Wainwright Ophthalmology Conference
Ticker: OKYO · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1849296
Sentiment: neutral
Topics: conference-participation, ophthalmology
TL;DR
OKYO Pharma is presenting at the H.C. Wainwright Ophthalmology Virtual Conference today, Aug 15th.
AI Summary
OKYO Pharma Ltd announced on August 15, 2024, that it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The conference is scheduled for Thursday, August 15th, and the announcement is filed as Exhibit 99.1 to this Form 6-K.
Why It Matters
Participation in industry conferences like this allows OKYO Pharma to present its developments and engage with potential investors and partners in the ophthalmology sector.
Risk Assessment
Risk Level: low — This filing is a routine announcement of participation in a conference and does not contain material financial or operational updates.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- H.C. Wainwright (company) — Organizer of the conference
- August 15, 2024 (date) — Date of announcement and conference
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to announce OKYO Pharma Ltd's participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
When is the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference being held?
The conference is being held on Thursday, August 15th, 2024.
What is the exact name of the company filing this report?
The exact name of the registrant is OKYO Pharma LTD.
Where is OKYO Pharma Ltd's principal executive office located?
OKYO Pharma Ltd's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Which exhibit contains the announcement of the conference participation?
The announcement is furnished as Exhibit 99.1 to this Report.
Filing Stats: 337 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-08-15 13:21:25
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-032567.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: August 15, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated August 15, 2024 4